The Overall Hemostasis Potential: A Laboratory Tool for the Investigation of Global Hemostasis

Abstract

A simple and rapid global haemostatic assay for determination of the overall hemostasis potential (OHP) in plasma represents a new approach in detecting alterations in the delicate balance between coagulation and fibrinolysis. The assay is based on repeated spectrophotometric registration of the fibrin-aggregation curve in platelet-poor plasma containing small amounts of exogenous thrombin, tissue-type plasminogen activator, and calcium. The overall coagulation potential and overall fibrinolytic potential are supplementary parameters of OHP, providing details of underlying changes in coagulation and/or fibrinolysis. The OHP assay was evaluated in connection with hypercoagulation in normal pregnancy, preeclampsia, some thrombophilias, coronary heart disease, diabetes, stroke, and vascular surgery as well as with hypocoagulability, especially in patients with hemophilia A or B. Preliminary results also indicate the possible usefulness of the assay in monitoring anticoagulant treatments. Large prospective clinical trials are needed before the method can be recommended for routine clinical application.

Short-term supplementation with Aronia melanocarpa extract improves platelet aggregation, clotting, and fibrinolysis in patients with metabolic syndrome

“…In this group, correlations were observed between the measured kinetic parameters and some of the other typical methods of hemostasis evaluation, as well as between factors such as sex, age, smoking, alcohol consumption, obesity, and physical activity [24]. Antovic [25], by means of spectrophotometric measurement of the overall potential for coagulation (OHP) and fibrinolysis (OFP), showed the existence of correlations between these parameters and different concentrations of coagulation factors (II, V, VII, VIII, IX, X, XI) during in vitro tests. The OHP assay was also evaluated in connection with hypercoagulation in normal pregnancy, preeclampsia, some thrombophilias, coronary heart disease, diabetes, stroke, and vascular surgery, as well as with hypocoagulability.…”

“…The OHP assay was also evaluated in connection with hypercoagulation in normal pregnancy, preeclampsia, some thrombophilias, coronary heart disease, diabetes, stroke, and vascular surgery, as well as with hypocoagulability. The possible usefulness of the assay in monitoring anticoagulant treatment was also revealed [25]. …”

Integrated laboratory coagulation tests in hypercoagulation diagnosis and thrombosis risk assessment. Part II. The sensitivity of integral tests to hypercoagulable states

“…Существует несколько вариаций метода одновре-менной регистрации тромбина и плазмина [63][64][65]. Усиленное свертывание и подавленный фибринолиз выявлены методом суммарного гемостатического по-тенциала (overall hemostasis potential) у пациентов, страдающих диабетом с микроциркуляторными осложнениями, у больных с преэклампсией, пожилых женщин с коронарной болезнью сердца [63].…”

“…Усиленное свертывание и подавленный фибринолиз выявлены методом суммарного гемостатического по-тенциала (overall hemostasis potential) у пациентов, страдающих диабетом с микроциркуляторными осложнениями, у больных с преэклампсией, пожилых женщин с коронарной болезнью сердца [63]. Хотя дан-ные пока очень скудные, метод кажется интересным, так как это единственная альтернатива ТЭГ для оцен-ки функции фибринолиза.…”

Utility of Clot Formation and Lysis Assay to Monitor Global Coagulation State of Patients with Severe Acute Pancreatitis

“…The basis of the CloFAL assay is the continuous registration of thrombin generation and lysis under in vitro conditions and simulates more closely the in vivo balance between pro-coagulants and anti-coagulants in patients with various hemostatic disorders, when compared to traditional coagulation tests [9]. CloFAL has been used to assess coagulation and fibrinolysis in pregnancy, some thrombophilias, coronary heart disease, diabetes, stroke, and hemophilia [10]. Our study was undertaken to evaluate the contribution of the CloFAL assay to monitor coagulation and fibrinolysis in patients with SAP.…”